Year: 2024
Type: article
Abstract: Treatment of diseases of oxidative stress through activation of the antioxidant nuclear factor E2-related factor 2 (NRF2) is limited by systemic side effects. We chemically functionalize the NRF2 activator monomethyl fumarate to require Baeyer–Villiger oxidation for release of the active drug at sites of oxidative stress. This prodrug reverses chronic pain in mice with reduced side effects and could be applied to other disorders of oxidative stress. Peroxides localized at oxidative stress sites trigger prodrug release for treating chronic pain in mice.
Source: Nature Biotechnology
Authors: Thomas D. Avery, Jiahe Li, Dion J. L. Turner, Mohd S. U. Rasheed, Fisher R. Cherry, Damian L. Stachura, Fátima Rivera-Escalera, David M. Ruiz, Michael J. Lacagnina, Caitlyn M. Gaffney, Clarissa Aguilar, Jingxian Yu, Yang Wang, Huan Xie, Dong Liang, Andrew J. Shepherd, Andrew D. Abell, Peter M. Grace
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $12,290
Funders: U.S. Department of Health and Human Services, Cancer Prevention and Research Institute of Texas, Department of Education and Training, National Institutes of Health, University of Texas MD Anderson Cancer Center, Australian Research Council, National Cancer Institute, National Institute of Neurological Disorders and Stroke, National Institute on Minority Health and Health Disparities
Awards: G111615301, G1803932301, G2480026445, G293715275, G4276892241, G4505098931, G5364420535, G5505331375, ARC Centre of Excellence for Nanoscale BioPhotonics, G623418118, Bio-inspired molecular electronics: from nanoscience to nanotechnology, GCC Center for Comprehensive PK/PD and Formulation, G8855705351, G9000034222, Center for Biomedical and Health Research at TSU
OpenAlex ID: W4404045776